Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brensocatib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC known ✓ | P53634 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brensocatib SCHEMBL26072864 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL29363739 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30025888 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30901221 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30025600 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL19813196 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL16932317 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30025597 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL19826706 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL26072928 | 1.00 | CTSC (1.00) | CTSCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159525-A | Specific N- (1-cyano-2-phenethyl) -1, 4-oxaazepane-2-carboxamides for the treatment of chronic sinusitis | 英斯梅德股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2023076615-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | INSMED INCORPORATED (US) | 2023-05-04 | — | — | WO | claimed |
| CN-118159525-A | Specific N- (1-cyano-2-phenethyl) -1, 4-oxaazepane-2-carboxamides for the treatment of chronic sinusitis | 英斯梅德股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230310453-A1 | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATING DIPEPTIDYL PEPTIDASE 1-MEDIATED CONDITIONS | INSMED INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| CN-116157687-A | Methods for extracting neutrophil serine protease and treating dipeptidyl peptidase 1 mediated disorders | 英斯梅德股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310453-A1 | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATING DIPEPTIDYL PEPTIDASE 1-MEDIATED CONDITIONS | PRSS3, SERPINB1, DPP3 | CTSC 7/4885KCNH2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.